Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Dividends
Dividends
Stock Price
About Ikena Oncology Inc
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. The company is headquartered in Boston, Massachusetts and currently employs 34 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The firm's lead targeted oncology program, IK-930, is a transcriptional enhanced associate domain 1 (TEAD1) selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The firm's second clinical-stage program targets the RAS signaling pathway with IK-595, a novel MEK-RAF molecular glue. The company has IK-175 aryl hydrocarbon receptor (AHR) antagonist program that completed Phase 1 clinical trial. Its partnering portfolio also includes several other immune oncology programs that are available for potential sale or outlicensing, including PY314, a Phase 2 ready TREM2 antagonist, PY159, a Phase 2 ready TREM1 antagonist, and PY265, an IND-ready MARCO antagonist.
Industry: Biological Products, (No Diagnostic Substances) Peers: Lyra Therapeutics Inc CorMedix Inc DURECT Corp Johnson & Johnson MariMed Inc Paratek Pharmaceuticals, Inc. scPharmaceuticals Inc Verrica Pharmaceuticals Inc
